Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2 results

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all The following terms were ignored: [, ]
Page 1
[Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis].
Tappeiner C, Rath T, Heiligenhaus A. Tappeiner C, et al. Klin Monbl Augenheilkd. 2018 May;235(5):562-567. doi: 10.1055/a-0586-3931. Epub 2018 May 8. Klin Monbl Augenheilkd. 2018. PMID: 29739025 German.
To achieve long-term ocular quiescence, to prevent uveitic secondary complications, to allow corticosteroid sparing and to avoid corticosteroid-related adverse effects, the application of immunosuppressive drugs (disease modifying antirheumatic drug
To achieve long-term ocular quiescence, to prevent uveitic secondary complications, to allow corticosteroid sparing and to avoid corticoster …
[Therapeutic Concepts for Treatment of Patients with Non-infectious Uveitis Biologic Disease Modifying Antirheumatic Drugs].
Walscheid K, Pleyer U, Heiligenhaus A. Walscheid K, et al. Klin Monbl Augenheilkd. 2018 May;235(5):553-561. doi: 10.1055/a-0577-8006. Epub 2018 Apr 12. Klin Monbl Augenheilkd. 2018. PMID: 29649840 German.
Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of various non-infectious uveitis entities. Currently, the TNF-alpha-inhibitor Adalimumab is the only in-label therapeutic opt …
Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of vari …